vs
Side-by-side financial comparison of Insight Molecular Diagnostics Inc. (IMDX) and TaoWeave, Inc. (TWAV). Click either name above to swap in a different company.
Insight Molecular Diagnostics Inc. is the larger business by last-quarter revenue ($1.1M vs $622.0K, roughly 1.8× TaoWeave, Inc.). TaoWeave, Inc. runs the higher net margin — -448.2% vs -2015.4%, a 1567.1% gap on every dollar of revenue. On growth, TaoWeave, Inc. posted the faster year-over-year revenue change (10.5% vs -23.4%). Over the past eight quarters, Insight Molecular Diagnostics Inc.'s revenue compounded faster (154.4% CAGR vs -0.3%).
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
IMDX vs TWAV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1M | $622.0K |
| Net Profit | $-23.0M | $-2.8M |
| Gross Margin | 42.5% | 47.1% |
| Operating Margin | -2057.5% | -126.4% |
| Net Margin | -2015.4% | -448.2% |
| Revenue YoY | -23.4% | 10.5% |
| Net Profit YoY | 31.5% | -215.4% |
| EPS (diluted) | $-0.75 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1M | $622.0K | ||
| Q3 25 | $260.0K | $601.0K | ||
| Q2 25 | $518.0K | $592.0K | ||
| Q1 25 | $2.1M | $622.0K | ||
| Q4 24 | $1.5M | $563.0K | ||
| Q3 24 | $115.0K | $578.0K | ||
| Q2 24 | $104.0K | $611.0K | ||
| Q1 24 | $176.0K | $626.0K |
| Q4 25 | $-23.0M | $-2.8M | ||
| Q3 25 | $-10.9M | $-2.3M | ||
| Q2 25 | $-9.7M | $-605.0K | ||
| Q1 25 | $-6.7M | $-672.0K | ||
| Q4 24 | $-33.5M | $-884.0K | ||
| Q3 24 | $-13.5M | $-1.0M | ||
| Q2 24 | $-4.5M | $-983.0K | ||
| Q1 24 | $-9.1M | $-1.1M |
| Q4 25 | 42.5% | 47.1% | ||
| Q3 25 | 53.5% | 40.6% | ||
| Q2 25 | 67.6% | 38.5% | ||
| Q1 25 | 62.0% | 40.0% | ||
| Q4 24 | 40.0% | 24.0% | ||
| Q3 24 | 43.5% | 13.7% | ||
| Q2 24 | 48.1% | 19.6% | ||
| Q1 24 | 25.6% | -0.5% |
| Q4 25 | -2057.5% | -126.4% | ||
| Q3 25 | -4249.2% | -133.4% | ||
| Q2 25 | -1900.0% | -115.4% | ||
| Q1 25 | -318.0% | -111.1% | ||
| Q4 24 | -2262.9% | -164.8% | ||
| Q3 24 | -11752.2% | -185.5% | ||
| Q2 24 | -4453.8% | -166.6% | ||
| Q1 24 | -5265.3% | -189.1% |
| Q4 25 | -2015.4% | -448.2% | ||
| Q3 25 | -4174.6% | -381.0% | ||
| Q2 25 | -1880.7% | -102.2% | ||
| Q1 25 | -312.0% | -108.0% | ||
| Q4 24 | -2255.1% | -157.0% | ||
| Q3 24 | -11733.0% | -179.9% | ||
| Q2 24 | -4355.8% | -160.9% | ||
| Q1 24 | -5186.9% | -181.5% |
| Q4 25 | $-0.75 | — | ||
| Q3 25 | $-0.34 | — | ||
| Q2 25 | $-0.30 | — | ||
| Q1 25 | $-0.26 | — | ||
| Q4 24 | $-2.19 | — | ||
| Q3 24 | $-0.98 | — | ||
| Q2 24 | $-0.36 | — | ||
| Q1 24 | $-1.13 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.6M | $2.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-31.5M | $7.0M |
| Total Assets | $25.8M | $8.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $2.3M | ||
| Q3 25 | $18.7M | $3.7M | ||
| Q2 25 | $24.3M | $10.8M | ||
| Q1 25 | $31.0M | $4.3M | ||
| Q4 24 | $8.6M | $5.0M | ||
| Q3 24 | $3.4M | $5.6M | ||
| Q2 24 | $9.3M | $5.9M | ||
| Q1 24 | $5.6M | — |
| Q4 25 | $-31.5M | $7.0M | ||
| Q3 25 | $-9.2M | $9.8M | ||
| Q2 25 | $1.1M | $11.3M | ||
| Q1 25 | $10.2M | $3.4M | ||
| Q4 24 | $-12.3M | $4.0M | ||
| Q3 24 | $9.7M | $4.7M | ||
| Q2 24 | $22.7M | $5.1M | ||
| Q1 24 | $11.6M | $4.4M |
| Q4 25 | $25.8M | $8.2M | ||
| Q3 25 | $43.9M | $10.9M | ||
| Q2 25 | $50.5M | $13.1M | ||
| Q1 25 | $60.4M | $4.8M | ||
| Q4 24 | $35.1M | $5.3M | ||
| Q3 24 | $70.2M | $6.0M | ||
| Q2 24 | $74.7M | $6.3M | ||
| Q1 24 | $71.0M | $5.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.5M | $-744.0K |
| Free Cash FlowOCF − Capex | $-7.0M | — |
| FCF MarginFCF / Revenue | -616.7% | — |
| Capex IntensityCapex / Revenue | 129.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-25.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.5M | $-744.0K | ||
| Q3 25 | $-4.5M | $-1.6M | ||
| Q2 25 | $-6.3M | $-37.0K | ||
| Q1 25 | $-5.9M | $-680.0K | ||
| Q4 24 | $-5.4M | $-255.0K | ||
| Q3 24 | $-5.5M | $-911.0K | ||
| Q2 24 | $-6.0M | $-1.6M | ||
| Q1 24 | $-3.8M | $-630.0K |
| Q4 25 | $-7.0M | — | ||
| Q3 25 | $-5.6M | — | ||
| Q2 25 | $-6.6M | — | ||
| Q1 25 | $-6.2M | — | ||
| Q4 24 | $-5.6M | — | ||
| Q3 24 | $-5.6M | — | ||
| Q2 24 | $-6.2M | — | ||
| Q1 24 | $-3.9M | — |
| Q4 25 | -616.7% | — | ||
| Q3 25 | -2135.4% | — | ||
| Q2 25 | -1279.5% | — | ||
| Q1 25 | -288.4% | — | ||
| Q4 24 | -374.5% | — | ||
| Q3 24 | -4884.3% | — | ||
| Q2 24 | -5931.7% | — | ||
| Q1 24 | -2189.8% | — |
| Q4 25 | 129.9% | — | ||
| Q3 25 | 403.8% | — | ||
| Q2 25 | 67.4% | — | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 14.4% | — | ||
| Q3 24 | 75.7% | — | ||
| Q2 24 | 183.7% | — | ||
| Q1 24 | 13.6% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
